Omega Therapeutics, Inc. Common Stock
OMGA
OMGA was delisted on the 24th of February, 2025.
44 hedge funds and large institutions have $231M invested in Omega Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 10
43% more capital invested
Capital invested by funds: $161M → $231M (+$69.5M)
0.25% more ownership
Funds ownership: 88.79% → 89.04% (+0.25%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2% less call options, than puts
Call options by funds: $198K | Put options by funds: $203K
6% less funds holding
Funds holding: 47 → 44 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.22M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.11M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$497K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$105K |
| 5 |
State Street
Boston,
Massachusetts
|
+$41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.05M |
| 2 |
Renaissance Technologies
New York
|
-$364K |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$321K |
| 4 |
BlackRock
New York
|
-$199K |
| 5 |
Rafferty Asset Management
New York
|
-$120K |
OMGA Hedge Fund Activity: Q3 2022 in Review
44 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Omega Therapeutics, Inc. Common Stock (OMGA) for Q3 2022, worth a combined $231M — up 43% from $161M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of OMGA and 4 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 15 added.
The largest buyer was Vanguard Group, adding an estimated $1.22M. The largest seller was Millennium Management, cutting an estimated $1.05M.
- 44 institutional investors held Omega Therapeutics, Inc. Common Stock (OMGA) as of Q3 2022, down from 47 in Q2 2022.
- Funds reported $231M of Omega Therapeutics, Inc. Common Stock stock for Q3 2022, up 43% quarter-over-quarter.
- 4 funds opened new Omega Therapeutics, Inc. Common Stock positions in Q3 2022 and 7 closed out, a net change of -3 holders.
- The largest Omega Therapeutics, Inc. Common Stock buyer in Q3 2022 was Vanguard Group, an estimated $1.22M added.
- The largest Omega Therapeutics, Inc. Common Stock seller in Q3 2022 was Millennium Management, an estimated $1.05M sold.
Based on aggregated 13F filings for Q3 2022.